(Q37642770)

21 August 2017

1 reference

title

Pazopanib: therapeutic developments (English)

1 reference

21 August 2017

main subject

pazopanib hydrochloride

1 reference

ChEBI release 2020-05-28

Suwicha Limvorasak

1

1 reference

21 August 2017

Edwin M Posadas

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

18

1 reference

21 August 2017

page(s)

3091-3102

1 reference

The biology of VEGF and its receptors

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Tumor-derived lymphangiogenic factors and lymphatic metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Pharmacogenetics of EGFR and VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Recurrent priapism related to oxaliplatin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

The use of thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Antiangiogenic therapy in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Neovascular age-related macular degeneration: potential therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

VEGF kinase inhibitors: how do they cause hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Tyrosine kinase inhibition and grey hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Review: side effects of approved molecular targeted therapies in solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

Late congestive heart failure after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903436493

10.1517/14656560903436493

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference